Long-term agalsidase beta therapy is associated with improvements in pain and quality of life among patients with Fabry disease

被引：0
|
作者：
Guffon, N.
Germain, D. P.
Waldek, S.
Banikazemi, M.
Bushinsky, D. A.
Charrow, J.
Lee, P.
Loew, T.
Vedder, A. C.
Wilcox, W. R.
机构：
[1] Hop Edouard Herriot, Lyon, France
[2] Hop Europeen Georges Pompidou, Paris, France
[3] Hope Hosp, Manchester, Lancs, England
[4] Mt Sinai Sch Med, New York, NY USA
[5] Univ Rochester, Sch Med, Rochester, NY 14627 USA
[6] Childrens Mem Hosp, Chicago, IL 60614 USA
[7] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
[8] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[10] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
CLINICAL THERAPEUTICS | 2007年 / 29卷
关键词：
D O I：
10.1016/S0149-2918(07)80154-8
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [21] The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa
    Mac Lochlainn, Dylan J.
    McKechnie, Douglas G. J.
    Mehta, Atul B.
    Hughes, Derralynn A.
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : 154 - 158
  • [22] Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
    Schiffmann, R
    Ries, M
    Timmons, M
    Flaherty, JT
    Brady, RO
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) : 345 - 354
  • [23] Fabrazyme® therapy in pediatric patients with Fabry disease:: improvements in quality-of-life measures
    Tylki-Szymanskal, A.
    Germain, D. P.
    Wraith, J. E.
    Guffon, N.
    Lien, Y. H.
    Tsimaratos, M.
    Vellodi, A.
    CLINICAL THERAPEUTICS, 2007, 29 : S31 - S32
  • [24] Occurrence of severe clinical events by time on agalsidase beta among patients with Fabry disease
    Ortiz, Alberto
    Cabrera, Gustavo H.
    Charrow, Joel
    Maruti, Sonia S.
    Politei, Juan
    Wanner, Christoph
    Warnock, David G.
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S89 - S90
  • [25] Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan
    Arakawa, Makoto
    Ikeda, Yoshinori
    Otaka, Hiromichi
    Iwashiro, Sanghun
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2024, 40
  • [26] A 10-year study documenting the long-term effectiveness of agalsidase-beta treatment in 52 adult patients with classic Fabry disease
    Germain, Dominique P.
    Charrow, Joel
    Desnick, Robert J.
    Guffon, Nathalie
    Kempf, Judy
    Lachmann, Robin H.
    Lemay, Roberta
    Linthorst, Gabor E.
    Packman, Seymour
    Scott, C. Ronald
    Waldek, Stephen
    Warnock, David G.
    Weinreb, Neal J.
    Wilcox, William R.
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S45 - S46
  • [27] EARLY ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY IN PSORIATIC ARTHRITIS IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN QUALITY OF LIFE
    Henkemans, S. Snoeck
    De Jong, P.
    Luime, J.
    Kok, M. R.
    Tchetverikov, I.
    Van der Helm-van Mil, A.
    Vis, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 21 - 21
  • [28] Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
    Germain, Dominique P.
    Charrow, Joel
    Desnick, Robert J.
    Guffon, Nathalie
    Kempf, Judy
    Lachmann, Robin H.
    Lemay, Roberta
    Linthorst, Gabor E.
    Packman, Seymour
    Scott, C. Ronald
    Waldek, Stephen
    Warnock, David G.
    Weinreb, Neal J.
    Wilcox, William R.
    JOURNAL OF MEDICAL GENETICS, 2015, 52 (05) : 353 - 358
  • [29] Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study
    Mignani, R
    Panichi, V
    Giudicissi, A
    Taccola, D
    Boscaro, F
    Feletti, C
    Moneti, G
    Cagnoli, L
    KIDNEY INTERNATIONAL, 2004, 65 (04) : 1381 - 1385
  • [30] Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies
    Tsurumi, Mina
    Suzuki, Shinya
    Hokugo, Jiro
    Ueda, Kazuo
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (05) : 589 - 601
12345